Antibacterial action of peptide F1 against colistin resistance E. coli SHP45 (mcr-1)

Area of Science:

• Microbiology
• Biochemistry
• Pharmacology

Background:

• Plasmid-mediated colistin resistance, mediated by mcr-1, poses a significant threat to public health.
• The mcr-1 mechanism confers resistance by modifying lipopolysaccharides (LPS), specifically lipid A.
• Colistin is a critical last-resort antibiotic for treating multidrug-resistant Gram-negative infections.

Purpose of the Study:

• To investigate the efficacy of antimicrobial peptide F1 against colistin-resistant E. coli SHP45 (mcr-1).
• To determine if antimicrobial peptide F1's mechanism of action is independent of lipopolysaccharides (LPS).
• To evaluate the potential of antimicrobial peptide F1 as a novel therapeutic agent against drug-resistant bacteria.

Main Methods:

• Antimicrobial peptide F1, previously isolated from Tibetan kefir, was tested against E. coli SHP45 (mcr-1).
• Bacterial growth inhibition assays were performed to assess peptide efficacy.
• Mechanism of action studies focused on membrane integrity and LPS interaction.

Main Results:

• Antimicrobial peptide F1 demonstrated significant inhibition of E. coli SHP45 (mcr-1) growth.
• The peptide's antibacterial activity was attributed to the disruption of bacterial inner and outer membranes, affecting the liposome structure.
• Crucially, the antimicrobial activity of peptide F1 was independent of lipopolysaccharides (LPS).

Conclusions:

• Antimicrobial peptide F1 effectively inhibits the growth of colistin-resistant E. coli.
• The mechanism involves direct bacterial membrane disruption, bypassing LPS modification.
• Peptide F1 represents a promising, safe therapeutic candidate to combat colistin resistance and emerging drug-resistant bacterial infections.